Cytokinetics (NASDAQ:CYTK) CEO Robert Blum Sells 7,500 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 7,500 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $73.44, for a total value of $550,800.00. Following the transaction, the chief executive officer owned 377,820 shares in the company, valued at approximately $27,747,100.80. This trade represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Stock Performance

CYTK opened at $69.31 on Wednesday. The company has a market cap of $8.62 billion, a PE ratio of -9.60 and a beta of 0.36. The stock has a 50-day moving average of $77.46 and a 200-day moving average of $72.80. Cytokinetics, Incorporated has a 52-week low of $47.22 and a 52-week high of $88.31.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The company had revenue of $28.62 million during the quarter, compared to the consensus estimate of $17.59 million. During the same period in the previous year, the business posted ($1.12) earnings per share. The firm’s revenue was down 57.1% on a year-over-year basis. On average, research analysts predict that Cytokinetics, Incorporated will post -5.98 earnings per share for the current year.

Institutional Investors Weigh In On Cytokinetics

Several hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its position in Cytokinetics by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company’s stock worth $194,214,000 after acquiring an additional 15,815 shares during the period. Principal Financial Group Inc. boosted its holdings in Cytokinetics by 11.9% in the 1st quarter. Principal Financial Group Inc. now owns 1,093,485 shares of the biopharmaceutical company’s stock valued at $72,072,000 after purchasing an additional 116,593 shares during the period. Frazier Life Sciences Management L.P. boosted its holdings in Cytokinetics by 5.0% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 934,642 shares of the biopharmaceutical company’s stock valued at $59,387,000 after purchasing an additional 44,197 shares during the period. Fisher Asset Management LLC grew its position in Cytokinetics by 8.0% in the 4th quarter. Fisher Asset Management LLC now owns 822,885 shares of the biopharmaceutical company’s stock worth $52,286,000 after purchasing an additional 61,298 shares during the last quarter. Finally, Norges Bank acquired a new stake in Cytokinetics in the 4th quarter worth $51,281,000.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Neutral Sentiment: CEO Robert I. Blum sold a combined 105,426 shares for approximately $7.34 million across September 14–15, reducing his direct holdings by roughly 22%. Because the sales were made under a pre-arranged Rule 10b5-1 plan, they may reflect scheduled portfolio diversification rather than a reaction to new company-specific information. SEC Form 4 filing
• Neutral Sentiment: Director Robert Landry separately sold 1,000 shares for $72,130 under a 10b5-1 plan. The relatively small transaction adds to the insider-selling activity but is not, by itself, a major fundamental signal. SEC director Form 4 filing
• Neutral Sentiment: Cytokinetics announced its ninth annual communications grant program, which will support cardiovascular-disease patient advocacy organizations. The initiative supports stakeholder engagement and awareness but is unlikely to materially affect near-term revenue or valuation. Grant program announcement
• Neutral Sentiment: Management presented at the Morgan Stanley Global Healthcare Conference, giving investors an opportunity to assess the company’s pipeline and commercialization plans. No clearly identified new major catalyst was provided in the supplied coverage. Morgan Stanley conference transcript
• Negative Sentiment: Commentary titled “Why Myqorzo Doesn’t Make Me a Buyer Yet” reflects investor caution about Myqorzo’s ability to establish a sufficiently attractive commercial opportunity. That skepticism can pressure CYTK until prescriptions, adoption, and revenue traction provide stronger evidence of the drug’s potential. Myqorzo investment commentary

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wall Street Zen cut shares of Cytokinetics from a “hold” rating to a “sell” rating in a research note on Saturday, August 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a research note on Friday. Barclays lifted their target price on shares of Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. HC Wainwright reissued a “buy” rating and set a $140.00 target price on shares of Cytokinetics in a research report on Monday, August 31st. Finally, JPMorgan Chase & Co. upped their price target on shares of Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Eighteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $103.37.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. The company applies expertise in muscle physiology and contractility to develop potential treatments for cardiovascular and neuromuscular diseases.

Its leading programs include aficamten, an investigational cardiac myosin inhibitor being developed for conditions involving abnormal heart-muscle contraction, including hypertrophic cardiomyopathy.